Weidemann DK, et al. - By performing this prospective longitudinal cohort analysis, researchers intended to validate the preliminary observations that soluble urokinase plasminogen activator receptor (suPAR) represents a new biomarker related to incident chronic kidney disease (CKD) and is an independent risk factor for CKD progression in children. The participants were selected from the Chronic Kidney Disease in Children (CKiD) Study, and included 565 individuals aged 1 to 16 years. At study entry and a 6-month follow-up interval, they measured plasma suPAR concentrations, divided by quartiles. In children with CKD, shorter time to kidney replacement therapy or halving of estimated glomerular filtrate rate (eGFR) was observed in relation to higher suPAR levels. A slight attenuation of this link was evident with the incorporation of eGFR in regression modeling but it continued to be a significant link for participants exhibiting the highest suPAR levels.